Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause

NCT01361308 is registered in ClinicalTrials.gov with Noven Therapeutics as lead sponsor.

NCT NCT01361308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01361308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Lead sponsor
Noven Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
February 29, 2012
Enrollment
614 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal symptoms